Hangzhou Aidecheng Pharmaceutical Technology

Hangzhou Aidecheng Pharmaceutical Technology is a Chinese biopharmaceutical company focused on the discovery and development of small molecule targeted therapies for oncology. Operating as a subsidiary of Nanjing Aidecheng Pharmaceutical Technology (Advenchen Laboratories Nanjing), the company leverages its expertise in medicinal chemistry to develop novel kinase inhibitors. Its lead pipeline candidate is AL8326, a multi-targeted tyrosine kinase inhibitor that inhibits VEGFR, FGFR, and Aurora kinase B, currently in Phase 3 clinical trials for small cell lung cancer. Additionally, the company is co-developing AL58805, a dual PI3K/mTOR inhibitor currently in Phase 1 clinical trials for solid tumors and hematological malignancies. Through its parent organization, the company is connected to the discovery of major commercialized oncology drugs in China, including apatinib and anlotinib.